Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Lilly's study showed that more patients treated with Zepbound had reductions in body weight of at least 10%, 15%, 20%, and 25% than those treated with Wegovy, while they also achieved a greater ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Additionally, a U.S. federal judge upheld the FDA’s decision to remove Eli Lilly’s weight loss and diabetes drugs, Zepbound and Mounjaro, from the list of medicines in short supply ...

These strategic shifts come as Lilly has seen substantial growth in recent years, with revenue increasing by 36% in the last twelve months to $49 billion, and anticipates continued success ... Eli ...